Keystone-SDA
The Danish pharmaceutical laboratory Novo Nordisk has seen its net profit fly by 32% in the 2nd quarter. The net profit of the producer of anti -diabetic ozempic which is all the rage for its weight loss properties reached 26.5 billion crowns.
(Keystone-ATS) From April to June, the turnover, of the group, which is struggling to remain competitive, amounted to 76 billion crowns (9.52 billion francs), taking 18% over a year, Novo Nordisk announced on Wednesday.
Eight days ago, the group had revised down its annual forecasts leading to a new tumble of the course of its title, in free fall for almost a year.
Already in May, the group, which will have, from August 7, a new boss, recruited internally, had the first time revised its perspectives.
“In May, we mainly thought that the low point had been reached, so everyone is a little surprised that it went so far, and now we do not want to see other disappointments,” the director of the Danish shareholders’ association Mikael Bak said.
“There are reasons to believe that the company is healthy, and that the institution as well as the products are good,” he said.
Novo Nordisk has reached heights thanks to the spectacular sales of Ozempic. This treatment is an analog of GLP-1 (abbreviation of glugaco-like peptide 1), a hormone secreted by the intestines which stimulates the secretion of insulin and rejects appetite by providing a feeling of satiety.
Sales of this medication increased by 15% in the first six months of the year.
The Danish laboratory remains, with 56.1% of market share, leader in the GLP-1 sector.
Wegovy sales, whose use to treat obesity has been approved in Britain, Denmark, France, Germany, Norway and the United States, increased from 78% from January to June, according to Novo Nordisk.
The drug has been available in China since mid-November.
The group also develops treatments against rare diseases including hemophilia, a sector whose turnover increased by 15% on the entire first half of 2025.